Skip to NavigationSkip to content

Cellnovo, Roche sign deal to integrate diabetes platforms

Published on 15/03/16 at 11:16am

Cellnovo Group (Paris: CLNV) on Tuesday said it has signed a deal with Swiss drug major Roche (Euronext: ROG) to integrate their diabetes products.

Under the deal Roche’s blood glucose monitoring (BGM) platforms Accu-Chek Aviva and Accu-Chek Performa will be integrated with Cellnovo’s diabetes management system.

Sophie Baratte, chief executive officer of Cellnovo, commented: “We are delighted to be partnering with Roche Diabetes Care, the world’s number one provider of blood glucose monitoring solutions. This collaboration is a significant endorsement of the Cellnovo technology and commercial approach and supports Cellnovo’s design objective of offering a unique all-in-one system for diabetes management.”

No financial details were disclosed.

Under the terms of the agreement, Cellnovo will have the rights to sell its integrated system, equipped with Roche’s Accu-Chek Aviva or Accu-Chek Performa platforms, across Europe.

The new Cellnovo systems will become available over the next month in all current markets, and will be made available in all future markets. The Roche strips used in Cellnovo’s new BGM integrated handsets will be available to patients via existing distribution channels.

Anjali Shukla

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches